Close Menu

NEW YORK – Singapore-based Lucence Diagnostics and China's MEDx (Suzhou) Translational Medicine announced on Wednesday a strategic partnership aimed at cancer in China.

Under the agreement, the firms will codevelop companion diagnostic tests for PD-L1 rearrangement to be used with anti-PD1/PD-L1 cancer immunotherapies. Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
03

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
23
Sponsored by
Inivata

In non-small cell lung cancer (NSCLC), liquid biopsy allows detection of driver mutations and can shed light on the development of resistance mutations during treatment.